Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Learn more about:
Related Clinical Trial
Bronchoscopic Laser Ablation of Peripheral Lung Tumors Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers Personalized PRRT of Neuroendocrine Tumors Clinical and Pathologic Studies in Neuroendocrine Tumors Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) Active Surveillance in Early Lung Cancer Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease Cabozantinib and Nivolumab for Carcinoid Tumors Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors Endoscopic Treatment of Bronchial Carcinoid Tumors Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors A Study of Axitinib in Advanced Carcinoid Tumors A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Brief Title

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Official Title

Multicenter Phase 2 Study of Nintedanib for Patients With Advanced Carcinoid Tumors

Brief Summary

      This phase II trial studies how well nintedanib works in treating patients with
      neuroendocrine tumors that have spread from where they started to nearby tissue or lymph
      nodes (locally advanced) or have spread from the primary site (place where they started) to
      other places in the body (metastatic). Nintedanib may stop the growth of tumor cells by
      slowing or stopping a certain type of receptor called vascular endothelial growth factor
      receptor (VEGFR) from attaching to its target. This may stop the growth of neuroendocrine
      tumors by blocking the growth of new blood vessels necessary for tumor growth.

Detailed Description


      I. To assess progression free survival (PFS), defined as the time interval from initiation of
      therapy, to its cessation for documentation of progressive disease (PD) or death.


      I. To assess the clinical response (complete response + partial response) in all patients
      with measurable disease (using standard Response Evaluation Criteria in Solid Tumors [RECIST]
      version [v]1.1 criteria).

      II. To assess overall survival (OS) in all patients. III. Assess changes in quality of life
      (QOL) throughout treatment using the European Organization for Research and Treatment of
      Cancer (EORTC) quality of life questionnaire (QLQ) - Gastrointestinal Neuroendocrine Tumors
      (NET) 21 (GI.NET21) questionnaire for carcinoid patients with gastrointestinal neuroendocrine
      tumors, in all patients who have filled out at least two QOL questionnaires and, will be
      reported by groups based on response (response, stable disease or progressive disease).

      IV. Steady-state pharmacokinetics (PK) of nintedanib, biomarkers, regulatory T cell (Treg)
      and cytokine expression and growth factors will be analyzed for all patients and reported in
      groups based on response.

      V. Gene mutations and copy number alterations analysis in the mammalian target of rapamycin
      (mTOR) pathway (will be performed only on the first 10 patients), protein expression of
      activation of protein kinase B (Akt) (as well as other downstream targets).

      VI. Toxicity (graded using the National Cancer Institute [NCI] Common Terminology Criteria
      for Adverse Events [CTCAE] version 4.0) will be closely monitored and all toxicities will be


      Patients receive nintedanib orally (PO) twice daily (BID) on days 1-28. Courses repeat every
      28 days in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days and then every 3
      months for 2 years.

Study Phase

Phase 2

Study Type


Primary Outcome


Secondary Outcome

 Change in QOL using the EORTC QLQ-GI.NET21 questionnaire


Carcinoid Tumor


Laboratory Biomarker Analysis

Study Arms / Comparison Groups

 Treatment (nintedanib)
Description:  Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

May 15, 2015

Completion Date

September 30, 2022

Primary Completion Date

September 30, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Patient must be on a stable dose of octreotide (Sandostatin®) long-acting release
             (LAR) or lanreotide for 3 months prior to study enrollment

          -  Patient must have histologically or cytologically confirmed well differentiated or
             moderately differentiated (low grade or intermediate grade) neuroendocrine tumor that
             is locally advanced or metastatic and not of pancreatic origin

          -  Measurable disease determined by computed tomography (CT) or magnetic resonance
             imaging (MRI)

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Life expectancy greater than 3 months

          -  Leukocytes >= 3,000/uL

          -  Absolute neutrophil count >= 1,500/uL

          -  Total bilirubin =< 2 mg/dL

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 x upper limit
             of normal (ULN) and bilirubin =< ULN for patients without liver metastases

          -  AST/ALT =< 2.5 x ULN and bilirubin =< ULN for patients with liver metastases

          -  Patients with Gilbert syndrome and bilirubin < 2 x ULN and normal AST/ALT

          -  Creatinine =< 1.5 mg/dl

          -  Prior treatment will be permitted including surgery (>= 4 weeks), cytotoxic
             chemotherapy (maximum of 2 prior regimens); radiation, interferon, targeted growth
             factors (>= 4 weeks); and prior treatment with octreotide, will be allowed

          -  Ability to swallow and retain oral medication

          -  Participants of child-bearing potential (both male and female) must agree to use
             adequate contraceptive methods (e.g., hormonal or barrier method of birth control;
             abstinence) prior to study entry; should a woman become pregnant or suspect she is
             pregnant while she or her partner is participating in this study, she should inform
             her treating physician immediately

          -  Participant or legal representative must understand the investigational nature of this
             study and sign an Independent Ethics Committee/Institutional Review Board approved
             written informed consent form prior to receiving any study related procedure

          -  Archival tissue of carcinoid biopsy must be available

        Exclusion Criteria:

          -  Uncontrolled hypertension, unstable angina, New York Heart Association grade II or
             greater congestive heart failure, unstable symptomatic arrhythmia requiring
             medication, or clinically significant peripheral vascular disease (grade II or

          -  Presence of brain metastases

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to day 0, or anticipated need for major surgical procedure during the course of
             the study, or fine needle aspirations or core biopsies within 7 days prior to day 0

          -  Significant proteinuria at baseline (>= 500 mg/24 hours [h])

          -  Serious non-healing wound, ulcer or bone fracture

          -  Evidence of bleeding diathesis or coagulopathy

          -  Recent (=< 6 months) arterial thromboembolic events, including transient ischemic
             attack, cerebrovascular accident, unstable angina, or myocardial infarction

          -  Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma,
             adenocarcinoid, goblet cell carcinoma, or small cell carcinoma

          -  Hepatic artery embolization or ablation of hepatic metastasis within 3 months of
             enrollment, prior peptide receptor radionuclide therapy (PRRT) within 4 months or any
             other cancer therapy within 4 weeks (as long as all toxicities are resolved)

          -  Intolerance or hypersensitivity to octreotide

          -  Severe or uncontrolled medical conditions

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant or nursing female participants

          -  Unwilling or unable to follow protocol requirements

          -  Any condition which in the investigator's opinion deems the participant an unsuitable
             candidate to receive study drug




18 Years - N/A

Accepts Healthy Volunteers



Renuka Iyer, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID

I 259114

Secondary IDs


Responsible Party


Study Sponsor

Roswell Park Cancer Institute


 National Cancer Institute (NCI)

Study Sponsor

Renuka Iyer, Principal Investigator, Roswell Park Cancer Institute

Verification Date

January 2021